Are there specific clinical phenotypes that are uniquely responsive to inhibition of type 2 cytokine-signaling proteins, or do patients across the moderate-to-severe spectrum of AD seem to respond with predictable success?

Are there specific clinical phenotypes that are uniquely responsive to inhibition of type 2 cytokine-signaling proteins, or do patients across the moderate-to-severe spectrum of AD seem to respond with predictable success?

Are there specific clinical phenotypes that are uniquely responsive to inhibition of type 2 cytokine-signaling proteins, or do patients across the moderate-to-severe spectrum of AD seem to respond with predictable success?


Created by

CMEducation Resources iQ&A Case-By-Case Atopic Dermatitis Medical Intelligence Zone

Presenter

Mark Lebwohl, MD

Mark Lebwohl, MD

Professor and Chairman, Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York USA